Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines

被引：1
|
作者：
Packer, L. [1 ]
Geng, X. [1 ]
Bonazzi, V. [1 ]
Mahon, C. [1 ]
Ju, R. [1 ]
Stephenson, S. [1 ]
Pollock, P. [1 ]
机构：
[1] Queensland Univ Technol, Sch Biomed Sci, Inst Hlth & Innovat, Translat Res Inst, Brisbane, Qld, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 61卷
关键词：
D O I：
10.1016/S0959-8049(16)61523-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [31] Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
    Ippen, Franziska Maria
    Grosch, Julia Katharina
    Subramanian, Megha
    Kuter, Benjamin Macfarlane
    Liederer, Bianca M.
    Plise, Emile G.
    Mora, Joana Liliana
    Nayyar, Naema
    Schmidt, Stephen Paul
    Giobbie-Hurder, Anita
    Martinez-Lage, Maria
    Carter, Scott L.
    Cahill, Daniel P.
    Wakimoto, Hiroaki
    Brastianos, Priscilla Kaliopi
    NEURO-ONCOLOGY, 2019, 21 (11) : 1401 - 1411
  • [32] Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
    Roper, Jatin
    Sinnamon, Mark J.
    Coffee, Erin M.
    Belmont, Peter
    Keung, Lily
    Georgeon-Richard, Larissa
    Wang, Wei Vivian
    Faber, Anthony C.
    Yun, Jihye
    Yilmaz, Oemer H.
    Bronson, Roderick T.
    Martin, Eric S.
    Tsichlis, Philip N.
    Hung, Kenneth E.
    CANCER LETTERS, 2014, 347 (02) : 204 - 211
  • [33] GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies
    Hong, Rebecca
    Edgar, Kyle
    Song, Kyung
    Steven, Schmidt
    Young, Amy
    Hamilton, Patricia
    Arrazate, Alfonso
    De La Cruz, Cecile
    Chan, Connie
    Pang, Jodie
    Salphati, Laurent
    Belvin, Marcia
    Nannini, Michelle
    Staben, Steven
    Friedman, Lori
    Sampath, Deepak
    CANCER RESEARCH, 2018, 78 (04)
  • [34] Detection of PI3K pathway activation in circulating tumor cells in PIK3CA mutated metastatic breast cancer as a putative predictive biomarker for PI3K inhibitor therapies
    Sharifi, Marina N.
    Sperger, Jamie M.
    Gilsdorf, Cole
    Wolfe, Serena K.
    Parkes, Amanda
    Wisinski, Kari B.
    O'Regan, Ruth M.
    Lang, Joshua M.
    CANCER RESEARCH, 2021, 81 (04)
  • [35] RETRACTED: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216 (Retracted Article)
    Walls, Marlena
    Baxi, Sangita M.
    Mehta, Pramod P.
    Liu, Kevin K-C
    Zhu, JinJiang
    Estrella, Heather
    Li, Chunze
    Zientek, Michael
    Zong, Qing
    Smeal, Tod
    Yin, Min-Jean
    CLINICAL CANCER RESEARCH, 2014, 20 (03) : 631 - 643
  • [36] RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models
    Pazolli, Ermira
    Kipp, Randy
    Boezio, Alessandro
    Gunaydin, Hakan
    Iskandar, Amanda
    Zubrowski, Matthew
    Williams, Bret
    Shortsleeves, Kelley
    Larivee, Alexandre
    McLean, Tom
    Michelsen, Klaus
    Zeng, Hongtao
    LaRochelle, Jonathan
    Manna, Joe
    DiPietro, Lucian
    Lescarbeau, Andre
    Mader, Mary
    Bennet, Bindu
    Wilbur, Jeremy
    Wang, Qi
    Pierce, Levi
    Martin, Iain
    Watters, James
    Fortin, Pascal
    Bergstrom, Donald
    CANCER RESEARCH, 2022, 82 (04)
  • [37] CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer
    Stanland, Lyla J.
    Ang, Hazel X.
    Hoj, Jacob P.
    Chu, Yunqiang
    Tan, Patrick
    Wood, Kris C.
    Luftig, Micah A.
    MOLECULAR CANCER RESEARCH, 2023, 21 (11) : 1148 - 1162
  • [38] Men1611 is a pi3k α/β selective and δ sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models
    Fiascarelli, Alessio
    Carrisi, Corrado
    Merlino, Giuseppe
    Capano, Stefania
    Bisignano, Diego
    Talucci, Simone
    Bressan, Alessandro
    Bellarosa, Daniele
    Bigioni, Mario
    Scaltriti, Maurizio
    Arribas, Joaquin
    Pellacani, Andrea
    Salerno, Massimiliano
    Binaschi, Monica
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
    Park, Ye-Lim
    Kim, Hwang-Phill
    Cho, Young-Won
    Min, Dong-Wook
    Cheon, Seul-Ki
    Lim, Yoo Joo
    Song, Sang-Hyun
    Kim, Sung Jin
    Han, Sae-Won
    Park, Kyu Joo
    Kim, Tae-You
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (02) : 389 - 401
  • [40] More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro
    Zheng, Jie
    Wang, Huan
    Yao, Jia
    Zou, Xianjin
    PHARMAZIE, 2014, 69 (01): : 38 - 42
12345